Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
Open Access
- 23 March 2009
- Vol. 14 (3), 1183-1226
- https://doi.org/10.3390/molecules14031183
Abstract
For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (PNAs) plays an important role. Three of them: pentostatin (DCF), cladribine (2-CdA) and fludarabine (FA) were approved by Food and Drug Administration (FDA) for the treatment of hematological malignancies. Recently three novel PNAs: clofarabine (CAFdA), nelarabine (ara-G) and forodesine (immucillin H, BCX-1777) have been synthesized and introduced into preclinical studies and clinical trials. These agents seem to be useful mainly for the treatment of human T-cell proliferative disorders and they are currently undergoing clinical trials in lymphoid malignancies. However, there are also several studies suggesting the role of these drugs in B-cell malignancies. This review will summarize current knowledge concerning the mechanism of action, pharmacologic properties, clinical activity and toxicity of PNAs accepted for use in clinical practice, as well as new agents available for clinical trials.Keywords
This publication has 222 references indexed in Scilit:
- Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic ToxicityCancer Research, 2008
- A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemiasBlood, 2007
- Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphomaCancer, 2006
- Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cellsBlood, 2006
- Efficacy and toxicity of 2-chlorodeoxyadenosine (cladribine)—2h infusion for 5 days—as first-line treatment for advanced low grade non-Hodgkin’s lymphomaEuropean Journal of Cancer, 1998
- FludarabineDrugs, 1997
- Liquid chromatographic study of acid stability of 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, 2-chloro-2′-deoxyadenosine and related analoguesJournal of Pharmaceutical and Biomedical Analysis, 1995
- PentostatinDrugs, 1993
- Hairy-Cell LeukemiaThe New England Journal of Medicine, 1987
- Remissions in Hairy-Cell Leukemia with Pentostatin (2′-Deoxycoformycin)The New England Journal of Medicine, 1987